The ESMO-MCBS is a validated and reproducible tool based on a rational, structured and consistent approach to the interpretation of published clinical trial data that can be used to determine an agent's relative grading in relation to its anticipated clinical benefit in a specific setting.
To find out more, please watch the introduction video below:
When to use each form
Form 1
Evaluation form 1 is used if the treatment is a new adjuvant or neoadjuvant therapy or if it's a new, potentially curative treatment.
Form 2a
Evaluation form 2a is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication either:
Form 2b
Evaluation form 2b is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication had a primary endpoint of progression free survival.
Form 2c
Evaluation form 2c is used for agents that are unlikely to be curative and where the clinical trial that led to its licensed indication had a primary endpoint of quality of life or response rate, or if it was a non-inferiority study.
Form 3
Evaluation form 3 is used for single-arm studies in orphan diseases or those with a high unmet need, where the clinical trial that led to its licensed indication had a primary endpoint of progression-free survival or overall response rate. Overall response rate includes all patients that had either a complete or partial response to treatment.
